Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Lexicon Pharmaceuticals Inc(LXRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LXRX
10/08/2026: LXRX (1-star) is currently NOT-A-BUY. Pass it for now.
Lexicon Pharmaceuticals is a specialized clinical-stage biotechnology company that recently transitioned into a commercial entity with the approval of INPEFA for heart failure. The firm's core strength lies in its proprietary drug discovery platform and its ability to advance therapies for high-unmet-need areas. The primary investment story rests on the successful commercial adoption of INPEFA and the potential future success of its neuropathic pain candidate, LX9211. Risks are significant, centered on the challenges of a first-time commercial launch, high cash burn, and intense competition from much larger pharmaceutical firms. This stock is best suited for growth-oriented investors with a high risk tolerance who are monitoring the sales trajectory of INPEFA and key clinical trial updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential upside through its clinical pipeline, but growth is highly dependent on binary clinical outcomes. |
| Momentum investor | Weak fit | The stock lacks consistent long-term upward momentum, making it less suitable for trend-following strategies. |
| Value investor | Weak fit | The company lacks the positive earnings history and asset-heavy stability typically required for value investing. |
| Dividend investor | Weak fit | Lexicon does not pay a dividend and is reinvesting all capital into development. |
| Low-risk investor | Weak fit | The high volatility and clinical risk inherent in biotech development are incompatible with low-risk investment profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience extreme price swings based on clinical trial results and regulatory news. |
| Valuation risk | Medium / high | Valuations are often speculative and based on long-term projections of unproven drug assets. |
| Competition risk (Pharma) | High | Large incumbents with significant resources can outspend or out-market smaller firms. |
| Business quality | Medium | The company is transitioning to a commercial model, which is a complex and capital-intensive shift. |
| Dividend income | Low / none | There is no current yield, as the company prioritizes cash for growth. |
| Execution risk | High | The company must effectively launch its first major commercial product while advancing pipeline clinical trials. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -30.8% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/08/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 783.12M USD | Price to earnings Ratio - | 1Y Target Price 4.55 |
Price to earnings Ratio - | 1Y Target Price 4.55 | ||
Volume (30-day avg) 3.1M shares | Beta 1.08 | 52 Weeks Range 1.10 - 2.68 | Updated Date 10/08/2026 |
52 Weeks Range 1.10 - 2.68 | Updated Date 10/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.16 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Direct sales of INPEFA in the United States. | Revenue comes from doctors prescribing their heart failure drug. |
| Licensing & Collaboration | Potential milestone payments and royalties from drug partnerships. | They may receive one-time payments for sharing development rights. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 783.05M | Price to Sales(TTM) 18.88 |
Enterprise Value 783.05M | Price to Sales(TTM) 18.88 | ||
Enterprise Value to Revenue 18.88 | Enterprise Value to EBITDA 16.57 | Shares Outstanding 444.96M | Shares Floating 218.99M |
Shares Outstanding 444.96M | Shares Floating 218.99M | ||
Percent Insiders 1.12 | Percent Institutions 83.9 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.